0.80

24.53% -0.26

After Hours: .78 -0.02 -2.50%

60 Degrees Pharmaceuticals Inc (SXTP)

Overview News Price History Why SXTP Down? Discussions Forecast

60 Degrees Pharmaceuticals Inc stock is traded at $0.80, with a volume of 2.68M. It is down -24.53% in the last 24 hours and down -37.01% over the past month. 60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The firm's pipeline products under development cover development programs for COVID-19, fungal, tick-borne, and other viral diseases.

Previous Close:

$1.06

Open:

$0.9656

24h Volume:

2.68M

Relative Volume:

1.81

Market Cap:

$1.84M

Revenue:

$502.40K

Net Income/Loss:

$-7.91M

P/E Ratio:

-0.0802

EPS:

-9.972

Net Cash Flow:

$-4.32M

1W Performance:

-8.98%

1M Performance:

-37.01%

6M Performance:

-59.58%

1Y Performance:

-78.31%

1-Day Range:

$0.77

$0.9899

1-Week Range:

$0.75

$1.20

52-Week Range:

$0.7015

$7.1988

60 Degrees Pharmaceuticals Inc Stock (SXTP) Company Profile

Name

60 Degrees Pharmaceuticals Inc

Sector

Healthcare (1174)

Industry

Biotechnology (678)

Phone

202-327-5422

Address

1025 CONNECTICUT AVENUE NW, WASHINGTON

Employee

Twitter

Next Earnings Date

Latest SEC Filings

SXTP's Discussions on Twitter

Compare SXTP with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
SXTP 60 Degrees Pharmaceuticals Inc	0.80	1.84M	502.40K	-7.91M	-4.32M	-9.972
VRTX Vertex Pharmaceuticals Inc	438.40	112.90B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	683.08	75.06B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	665.68	40.45B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	277.16	35.75B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	120.88	28.98B	3.30B	-501.07M	1.03B	-2.1146

60 Degrees Pharmaceuticals Inc Stock (SXTP) Latest News

02:21 AM

60 Degrees Pharma Announces Closing of $1.043 Million - GlobeNewswire

02:21 AM

02:20 AM

60 Degrees Pharma Secures Fresh Capital: Inside the $1M Financing Deal That's Turning Heads - StockTitan

02:20 AM

08:30 AM

60 Degrees Pharma Announces $1.043 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - The Manila Times

Jan 29, 2025

Pharma Company's $1M Cash Injection Comes with Hidden UpsideComplete Analysis - StockTitan

Jan 29, 2025

US Futures Point To Cautious Start As Investors Await Fed's Rate Decision: Tesla, Microsoft, Meta Among Stocks In Focus Ahead Of Earnings - Benzinga

Jan 29, 2025

60 Degrees Pharmaceuticals obtains IRB approval for chronic babesiosis therapy trial - Yahoo! Voices

Jan 29, 2025

Why F5 Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket - Benzinga

Jan 29, 2025

Jan 28, 2025

60 Degrees Pharmaceuticals Gets Investigational Review Board Approval for Babesiosis Phase 2 Study - Marketscreener.com

Jan 28, 2025

60 Degrees Pharmaceuticals, Inc. Announces the Approval of an Investigational Review Board Commissioned Phase II Clinical Study - Marketscreener.com

Jan 28, 2025

60 Degrees Pharma Announces IRB Approval of Phase II Study to Evaluate Tafenoquine for Chronic Babesiosis - GlobeNewswire

Jan 28, 2025

Revolutionary Tick-Borne Disease Treatment Gets Green Light: 400,000 Patients Await New Hope - StockTitan

Jan 28, 2025

Jan 21, 2025

Titan Pharma (NASDAQ:TTNP) Stock Quotes, Forecast and News Summary - Benzinga

Jan 21, 2025

Jan 20, 2025

Palatin Technologies Inc (AMEX: PTN) Analysts Expect It Could Climb 93.76% From Current Levels. - Stocks Register

Jan 20, 2025

60 Degrees Pharmaceuticals Inc (NASDAQ: SXTP) Jumps 0.32 Percent In Recent Trading, What Questions Do You Have? – Stocks Register - Stocks Register

Jan 20, 2025

Weiss Ratings Reiterates Sell (E+) Rating for 60 Degrees Pharmaceuticals (NASDAQ:SXTP) - Defense World

Jan 20, 2025

Jan 15, 2025